Skip to content

US · ATR · MEDICAL - INSTRUMENTS & SUPPLIES

AptarGroup, Inc. (ATR) intrinsic value and stock valuation

$140.08as of 2026-11-21 · Mkt cap 8.64B

Data updated · price as of 2026-11-21

OvervaluedIC value is 20–50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

AptarGroup, Inc. DCF and intrinsic value

InvestorsCraft values ATR with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from ATR’s statements →

AptarGroup, Inc. Graham Number

Graham Number: $74.47d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Instruments & Supplies Crystal Lake, IL 60014 aptar.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$3.78B+5.2% 5y CAGRd
20112025
Net income
$392.8M+12.9% 5y CAGRd
20112025
Free cash flow
$299.6M-1.2% 5y CAGRd
20112025
Total equity
$2.71B+7.9% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$3.78B$3.58B$3.49B$3.32B$3.23B
Operating income$512.3M$496.5M$404M$379.3M$347.4M
Net income$392.8M$374.5M$284.5M$239.3M$244.1M
EPSd$5.89M$5.53M$4.25M$3.59M$3.61M
Operating cash flow$570M$643.4M$575.2M$478.6M$363.4M
Capital expenditure-$-270.42M-$-294.19M-$-318.4M-$-315.62M-$-307.94M
Free cash flow$299.6M$349.2M$256.8M$163M$55.5M
Total assets$5.25B$4.43B$4.45B$4.2B$4.14B
Total debt$1.53B$1.08B$1.18B$1.22B$1.24B
Net debt$1.13B$852.2M$961M$1.08B$1.12B
Total equity$2.71B$2.49B$2.32B$2.07B$1.98B
Cash and short-term investments$409.5M$226.2M$223.6M$141.7M$123.7M
Income statement
20252024202320222021
Revenue$3.78B$3.58B$3.49B$3.32B$3.23B
Cost of revenue$2.66B$2.23B$2.22B$2.16B$2.07B
Gross profit$1.12B$1.36B$1.26B$1.16B$1.16B
Research and development expenses$105.1M$0.00$0.00$0.00$99.8M
Selling, general and administrative expenses$499.9M$582.2M$565.8M$544.3M$551.2M
Other expenses$0.00$276.8M$293.6M$240.3M$158.3M
Operating expenses$605M$859M$859.4M$784.6M$809.3M
Cost and expenses$3.26B$3.09B$3.08B$2.94B$2.88B
Interest income$11.7M$12.1M$4.37M$2.7M$3.67M
Interest expense$52.7M$43.9M$40.4M$40.8M$30.3M
Depreciation and amortization$287.4M$263.8M$248.6M$233.7M$234.9M
Ebitda$831.5M$777.5M$663.8M$609.4M$586.8M
Operating income$512.3M$496.5M$404M$379.3M$347.4M
Total other income/expenses, net-$-20.96M-$-26.73M-$-29.19M-$-44.57M-$-25.69M
Income before tax$491.4M$469.8M$374.8M$334.7M$321.7M
Income tax expense$98.9M$95.6M$90.7M$95.2M$78M
Net income$392.8M$374.5M$284.5M$239.3M$244.1M
Weighted average shares outstanding$65.7M$66.3M$65.6M$65.4M$65.7M
Weighted average diluted shares outstanding$66.7M$67.7M$66.9M$66.7M$67.7M
Balance sheet
20252024202320222021
Cash and short-term investments$409.5M$226.2M$223.6M$141.7M$123.7M
Net receivables$803.8M$658.1M$677.8M$677M$671.4M
Inventory$537.9M$461.8M$513.1M$486.8M$441.5M
Total current assets$1.89B$1.48B$1.55B$1.43B$1.36B
Property, plant and equipment, net$1.74B$1.51B$1.54B$1.4B$1.34B
Goodwill and intangible assets$1.33B$1.19B$1.25B$1.26B$1.34B
Long-term investments$131M$146.3M$49.2M$52.3M$59.5M
Total non-current assets$3.36B$2.95B$2.9B$2.77B$2.78B
Total assets$5.25B$4.43B$4.45B$4.2B$4.14B
Accounts payable$340.6M$296M$328.6M$320.3M$285.3M
Short-term debt$343.5M$338.3M$458.2M$126M$289.6M
Deferred revenue$74.8M$64.4M$60.5M$80.2M$87M
Total current liabilities$1.17B$1.07B$1.25B$917.2M$982.5M
Long-term debt$1.19B$737.8M$726.5M$1.1B$955M
Deferred revenue, non-current$0.00$0.00$37.8M$25.4M$21.9M
Total non-current liabilities$1.37B$878.1M$879.3M$1.22B$1.17B
Capital lease obligations$47.9M$49.7M$45.3M$46.2M$51.8M
Total liabilities$2.54B$1.95B$2.13B$2.14B$2.16B
Common stock$730K$720K$720K$710K$700K
Retained earnings$2.64B$2.37B$2.11B$1.93B$1.79B
Accumulated other comprehensive income (loss)-$-186.38M-$-429.48M-$-308.73M-$-341.37M-$-316.04M
Total equity$2.71B$2.49B$2.32B$2.07B$1.98B
Total investments$138.1M$148.6M$49.2M$52.3M$60.2M
Total debt$1.53B$1.08B$1.18B$1.22B$1.24B
Net debt$1.13B$852.2M$961M$1.08B$1.12B
Cash flow statement
20252024202320222021
Net income$392.8M$374.2M$284.2M$239.6M$243.6M
Depreciation and amortization$287.4M$263.8M$248.6M$233.7M$234.9M
Stock-based compensation$0.00$47.7M$41.3M$40.9M$38.9M
Change in working capital-$-125.45M-$-32.26M$5.75M-$-45M-$-169.69M
Accounts receivable-$-73.89M-$-18.08M$15.4M-$-27.94M-$-123.25M
Inventory-$-10.65M$21.9M-$-10.64M-$-60.35M-$-79.96M
Accounts payable-$-18.27M-$-23.7M$14.6M$55.1M$52.3M
Net cash provided by operating activities$570M$643.4M$575.2M$478.6M$363.4M
Investments in property, plant and equipment-$-275.44M-$-294.19M-$-318.4M-$-315.62M-$-307.94M
Acquisitions, net-$-55.87M$0.00-$-16.57M-$-4.1M-$-148.42M
Net cash used for investing activities-$-330.64M-$-396.72M-$-324.46M-$-295.64M-$-457.24M
Common stock issued$18.9M$0.00$0.00$0.00$0.00
Common stock repurchased-$-365M-$-68.64M-$-47.55M-$-92.13M-$-78.15M
Dividends paid-$-120.78M-$-114.06M-$-103.68M-$-99.46M-$-98.51M
Net cash used for financing activities-$-78.26M-$-225.34M-$-171.55M-$-162.1M-$-81.52M
Net change in cash$178.1M$200K$81.4M$19.8M-$-182.04M
Cash at end of period$402.4M$224.3M$224.1M$142.7M$122.9M
Operating cash flow$570M$643.4M$575.2M$478.6M$363.4M
Capital expenditure-$-270.42M-$-294.19M-$-318.4M-$-315.62M-$-307.94M
Free cash flow$299.6M$349.2M$256.8M$163M$55.5M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About AptarGroup, Inc.

        AptarGroup, Inc. specializes in developing and manufacturing solutions for dispensing, sealing, and advanced material science, catering to a broad spectrum of industries such as beauty, personal care, home care, and the pharmaceutical sector (including prescription drugs, consumer health care, and injectables), alongside the food and beverage markets. Its operations are structured into three key segments: Pharma, Beauty + Home, and Food + Beverage. The Pharma division offers critical components for the pharmaceutical industry, including pumps for nasal allergy remedies, metered dose inhaler valves vital for managing respiratory conditions like asthma and chronic obstructive pulmonary disease (COPD), elastomeric primary packaging for injectables, and sophisticated active material science innovations. The Beauty + Home segment primarily supplies the personal care and home care sectors with essential products such as pumps, various closures, aerosol valves, accompanying accessories, and sealing mechanisms. It also furnishes the beauty market with pumps and decorative elements. For the food and beverage industries, its Food + Beverage segment delivers a variety of dispensing and non-dispensing closures, specialized elastomeric flow control components, spray pumps, and aerosol valves. AptarGroup markets its offerings globally, utilizing its internal sales team, complemented by independent representatives and distributors across Asia, Europe, Latin America, and North America. The company is engaged in a strategic partnership with PureCycle Technologies LLC to pioneer the integration of ultra-pure recycled polypropylene into advanced dispensing applications. Additionally, it collaborates with Sonmol on the development of a digital platform providing therapies and services, with a particular focus on respiratory and other health conditions. Established in 1992, AptarGroup, Inc. maintains its corporate headquarters in Crystal Lake, Illinois.

        CEO
        Stephan Tanda
        Employees
        14K
        Beta
        0.39

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of AptarGroup, Inc. (ATR)?

        AptarGroup, Inc. (ATR) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is ATR undervalued?

        ATR trades at a price of $140.08 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.